arrow
M

Martin R. Stockler

University of Queensland
H指数:65
被引数:2.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Insulin-Like Growth Factor Axis and Survival in Metastatic Hormone-Sensitive Prostate Cancer: Post-Hoc Analysis From the ENZAMET Phase 3 Trial

胰岛素样生长因子轴与转移性激素敏感型前列腺癌的生存:来自ENZAMET III期试验的事后分析

2026-09-300
OAAI
Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial

奥拉帕利在HR缺陷、转移性三阴性乳腺癌和铂敏感复发性卵巢癌中BRCA1/2无胚系突变患者中的疗效:EMBRACE二期临床试验

2026-07-080
OA
Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial

早期PSMA上调对恩扎卢胺±177Lu-PSMA-617治疗高危转移性去势抵抗性前列腺癌疗效的预测价值:随机II期ENZA-p试验的亚组研究

2026-04-010
PRE
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer

早期对转移性激素敏感型前列腺癌的 prostate-specific antigen (PSA) 阳性反应预测

2025-12-170
OAAI
Development and validation of a prognostic model incorporating patient reported outcomes for advanced gastric and esophageal carcinoma (AGOC) using individual patient data from two AGITG randomized clinical trials

基于两项AGITG随机临床试验的个体患者数据,开发并验证一个整合患者报告结局的预后模型,用于预测晚期胃癌和食管癌(AGOC)。

2025-09-160
OAAI
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial

基线PSMA-PET总肿瘤体积和SUVmean在转移性去势抵抗性前列腺癌中的预后和预测价值:一项来自多中心、开放标签、随机、II期试验ENZA-p (ANZUP1901)的亚研究

2025-07-300
PRE
Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial

Lutetium-177-PSMA-617或cabazitaxel在转移性前列腺癌中的应用:随机II期therap试验的循环肿瘤DNA分析

2025-05-270
PRE
Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304)

循环脂质面板PCPro与转移性激素敏感前列腺癌临床结局的关联:ENZAMET III期随机试验(ANZUP 1304)的事后分析

2025-05-200
PRE
Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation-Positive NSCLC An Open-Label Phase 2 Trial (ILLUMINATE)

Durvalumab,Tremelimumab和铂类化疗在EGFR突变阳性NSCLC中的应用开放标签2期试验 (illumate)

2025-02-010
OA
Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [177Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 Trial

[TheraP研究]:转移性去势抵抗性前列腺癌患者接受[177Lu]Lu-PSMA-617与卡巴他赛治疗疗效反应的预后和预测模型的验证——一项来自随机、开放标签、Ⅱ期临床试验的事后分析

2025-02-013
OAAI
CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC)

CCTG BR.31:一项关于完全切除的非小细胞肺癌(NSCLC)辅助治疗中 durvalumab 的全球性、双盲、安慰剂对照、随机III期研究

2024-09-016
PRE
Health-related quality of life with comprehensive geriatric assessment guided care versus usual care in older adults with cancer: A systematic review and meta-analysis of randomized trials

老年癌症患者的健康相关生活质量综合评估指导护理与常规护理: 随机试验的系统评价和荟萃分析

2024-09-011
PRE
Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304)

ENZAMET(ANZUP 1304)研究中,转移性激素敏感性前列腺癌(mHSPC)高容量亚组内的临床预后因素

2024-09-010
PRE